Phosphorylcholine-coated stents

Journal of Long-Term Effects of Medical Implants

Volumn 12, Issue 4, 2002, Pages 231-250

  Lewis, Andrew L ^a   Stratford, Peter W ^a  

^a BIOCOMPATIBLES UK LTD   (United Kingdom)

Author keywords

Coronary stents; Hemocompatibility; Phosphorylcholine

Indexed keywords

ANGIOCARDIOGRAPHY; BIOMEDICAL ENGINEERING; BLOOD; BLOOD VESSELS; PATIENT TREATMENT; TISSUE;

STAINLESS STEEL STENTS;

IMPLANTS (SURGICAL);

ANTITHROMBOCYTIC AGENT; HEPARIN; PHOSPHORYLCHOLINE; STAINLESS STEEL;

ARTERY OCCLUSION; ARTICLE; BLOOD COMPATIBILITY; CLINICAL TRIAL; CORONARY ARTERY; CORONARY ARTERY THROMBOSIS; CORONARY STENT; DEVICE; DRUG DELIVERY SYSTEM; HUMAN; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; TRANSLUMINAL CORONARY ANGIOPLASTY;

EID: 0037000247     PISSN: 10506934     EISSN: None     Source Type: Journal    
DOI: 10.1615/jlongtermeffmedimplants.v12.i4.20     Document Type: Article

References (70)

1. Schatz RA, Baim DS, Leon M, et al. Clinical experience with the Palmaz-Schatz coronary stent: initial results of a multi-centre study. Circulation 1991; 83:148-161.
2. Serruys PW, Strauss BH, Beatt KJ, et al. Angiographic followup after placement of a self-expanding coronary artery stent. N Engl J Med 1991; 324:13-17.
3. Bantjes A. Clotting phenomena at the blood-polymer interface and development of blood compatible polymer surfaces. Brit Polym J 1978; 10:267-274.
4. Eeckhout E, Kappenberger L, Goy JJ. Stents for intracoronary placement: current status and future directions. JACC 1996; 27:757-765.
5. Pepine JC, Holmes DR, Block PC, et al. Coronary artery stents. JACC 1996; 28:782-794.
6. Balcon R, Beyar R, Chierchia S, et al. Recommendations on stent manufacture, implantation and utilization. Eur Heart J 1997; 18:1536-1547.
7. Kocsis JF, Llanos G, Holmer E. Heparin-coated stents. J Long-Term Effects Med Implants 2000; 10(1&2):19-45.
8. Cumberland DC, Gunn J, Malik N, Holt CM. Biomimicry I: PC. Semin Interv Cardiol 1998; 3:149-150.
9. Peng T, Gibula P, Yao K, Goosen MFA. Role of polymers in improving results from stenting in coronary arteries. Biomaterials 1996; 17(7):685-694.
10. Bertrand OF, Sipehia R, Mongrain R, et al. Biocompatibility aspects of new stent technology. JACC 1998; 32(3):562-571.
11. Sousa JE, Costa MA, Abizaid A, et al. Lack of neointimal proliferation after implantation of sirolimus-coated stents in human coronary arteries: a quantitative coronary angiography and three-dimensional intravascular ultrasound study. Circulation 2001; 103:801-809.
12. Chinn J, Mabrey J. Fashion platelets: new coats for coronary stents. MDVD magazine. March 1999;58-71.
13. Sigwart LI, Prasad S, Radke P, Nadra I. Prosthetic coating: new materials. J Invasive Cardiol 2001; 13(2):141-142.
14. Zwaal RFA, Comfurius P, van Deenen LLM. Membrane asymmetry and blood coagulation. Nature 1977; 268:358-360.
15. Hayward JA, Chapman D. Biomembrane surfaces as models for polymer design: the potential for haemocompatility. Biomaterials 1984; 5:135-142.
16. Durrani AA, Hayward JA, Chapman D. Biomembranes as models for polymer surfaces. II. The syntheses of reactive species for covalent coupling of phosphorylcholine to polymer surfaces. Biomaterials 1985; 7:121-125.
17. Hayward JA, Durrani AA, Shelton CJ, et al. Biomembranes as models for polymer surfaces III. Characterisation of a phosphorylcholine surface covalently bound to glass. Biomaterials 1986; 7:126-131.
18. Hayward JA, Durrani AA, Lu Y, et al. Biomembranes as models for polymer surfaces. IV. ESCA analyses of a phosphorylcholine surface covalently bound to hydroxylated substrates. Biomaterials 1986; 7:252-258.
19. Chapman D, Charles SA. A coat of many lipids - in the clinic. Chem Brit 1992; 28:253-256.
20. Driver MJ, Lewis AL. Preventing foul play. Chem Brit 1999; 35:42-45.
21. Ishihara K, Nomura H, Mihara T, Kurita K, Iwasaki Y, Nakabayashi N. Why do phospholipid polymers reduce protein adsorption? J Biomed Mater Res 1998; 39:323-330.
22. Lewis AL. Phosphorylcholine-based polymers and their use in the prevention of biofouling. Coll Surf B: Biointerfaces 2000; 18:261-275.
23. Lewis AL, Cumming ZC, Goreish HH, et al. Crosslinkable coatings from phosphorylcholine-based polymers. Biomaterials 2001; 22:99-111.
24. Regis R, Barragan P, Masson C, et al. Radial force of coronary stents: a comparative analysis. Catheter Cardiovasc Interv 1999; 46(3):380-391.
25. Bonan R, Paiement P, Tanguay J, et al. Recoil evaluation of a new stent with phosphorylcholine coating in porcine coronary arteries [abstract]. Eur Heart J 1997; 18 Suppl:153.
26. Hall B, Pearce DJ, Campbell EJ, et al. Enzyme-linked immunoabsorbant assay for biocompatibility testing. In: Lemm W, editor. The Reference Materials of the European Community: Results of Haemocompatibility Tests. London: Kluwer, 1992: 147-155.
27. Campbell EJ, O'Byrne V, Stratford PW, et al. Biocompatible surfaces using methacryloylphosphorylcholine laurylmethacrylate copolymers. ASAIO J 1994; 40(3):853-857.
28. Campbell EJ, Chronos NAF, Robinson KA, et al. Non-thrombogenic phosphorylcholine coatings for stainless steel. Transactions of the Society of Biomaterials 1995; 18:15.
29. Lewis AL, Tolhurst LA, Stratford PW. Analysis of a phosphorylcholine-based polymer coating on a coronary stent pre- and post-implantation. Biomaterials 2002; 23:1697-1706.
30. Chronos NAF, Robinson KA, Kelly AB, et al. Thromboresistant phosphorylcholine coating for coronary stents [abstract 3290]. Circulation 1995; 92(8):685.
31. Chronos NAF, Campbell EJ, Wilson DJ, et al. Improved haemocompatibility of artificial surfaces can be achieved by phosophorylcholine coating: a human ex vivo flowing blood model. Eur Heart J 1994; 15:312:P1645.
32. Hanson SR, Chronos NAE Cardiovascular device surface properties, thrombosis and healing. Transactions of the Society of Biomaterials 1997; 20:16.
33. Kuiper KK, Robinson KA, Chronos NAF, et al. Implantation of metal phosphorylcholine-coated stents in rabbit iliac and porcine coronary arteries. Circulation 1997; 96(Suppl 1):209.
34. Kuiper KK, Robinson KA, Chronos NAF, et al. Phosphorylcholine-coated stents in rabbit iliac and porcine coronary arteries. Scand Cardiovasc J 1998; 32:261-268.
35. Malik N, Gunn J, Shepherd L, et al. Phosphorylcholine-coated stents in porcine coronary arteries: in vivo assessment of biocompatibility. J Invasive Cardiol 2001; 13:193-201
36. Murphy JG, Schwartz RS, Edwards WD, et al. Percutaneous polymeric stents in porcine coronary arteries: initial experience with polyethylene terephthalate stents. Circulation 1992; 86: 1596-1604.
37. van der Giessen WJ, Lincoff AM, Schwartz RS, et al. Marked inflammatory sequelae to implantation of biodegradable and nonbiodegradable polymers in porcine coronary arteries. Circulation 1996; 94 (7):1690-1697.
38. van Beusekomm HMM, Whelan DM, Krabbendam SC, et al. Biocompatibility of phosphorylcholine coated stents in a coronary artery model. Circulation 1997; 96 (Suppl 1):29.
39. Whelan DM, van der Giessen WJ, Krabbendam SC, et al. Biocompatibility of phosphorylcholine-coated stents in normal porcine coronary arteries. Heart 2000; 83(3):338-345.
40. Tolhurst LA. The analysis of post-implant phosphorylcholine coating on cardiovascular stents. Spring Medical Device Technology Conference Proceedings, 1999:427-441.
41. Lewis AL, Furze JD, Small S, et al. Long-term stability of a coronary stent coating post-implantation. J Biomed Mater Res, Appl Biomat 2002; 63:699-705.
42. Carlos TM, Harlan JM. Leukocyte-endothelial adhesion molecules. Blood 1994; 4:2068-2101.
43. Chong BH, Murray B, Berndt MC, et al. Plasma P-selectin is increased in thrombotic consumptive platelet disorders. Blood 1994; 83:1535-1541.
44. Jang T, Lincoff M, Plow E, et al. Cell adhesion molecules in coronary artery disease. JACC 1994; 24:1591-1601.
45. Atalar E, Haznedaroli I, Aytemir K, et al. Effects of stent coating on platelets and endothelial cells after intracoronary stent implantation. Clin Cardiol 2001; 24:159-164.
46. Rupprecht HJ, Darius H, Borkowski U, et al. Comparison of antiplatelet effects of aspirin, ticlopidine, or their combination after stent implantation. Circulation 1998; 97:1046-1052.
47. Gawaz M, Neumann F-J, Ott I, et al. Role of activation-dependent platelet membrane glycoproteins in development of subacute occlusive coronary stent thrombosis. Coron Artery Dis 1997; 8:121-128.
48. Galli M, Sommariva L, Prati F, et al. Acute and mid-term results of phosphorylcholine-coated stents in primary coronary stenting for acute myocardial infarction. Catheteter Cardiovasc Interv 2001; 53:182-187.
49. Schomig A, Neumann FJ, Kastrati A, et al. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary artery stents. N Engl J Med 1996; 334: 1084-1089.
50. Ahmed T, Webb JG, Carere RR, et al. Coronary stenting for acute myocardial infarction. Am J Cardiol 1995; 76:77-80.
51. Nuemann FJ, Walter H, Richardt G, et al. A coronary Palmaz-Schatz stent implantation in acute myocardial infarction. Heart 1996; 75:121-126.
52. Garcia E, Spaulding C, Corocos T, et al. Stent implantation in acute myocardial infarction. Am J Cardiol 1996; 77:451-454.
53. Ferguson JJ, Dougherty KG, Gaos CM, et al. Relation between procedural activated coagulation time and outcome after percutaneous transluminal coronary angioplasty. JACC 1994; 23: 1061-1065.
54. Koch KT, Piek JJ, de Winter RJ, et al. Safety of low dose heparin after elective coronary angioplasty. Heart 1997; 77:517-522.
55. Kereiakes DJ, Broderick TM, Whang DD, et al. Partial reversal of heparin anticoagulation by intravenous protamine in abciximab-treated patients undergoing percutaneous intervention. Am J Cardiol 1997; 80:633-634.
56. Kuiper KKJ, Nordrehaug JE. Early mobilization after protamine reversal of heparin following implantation of phosphorylcholine coated stents in totally occluded coronary arteries. Am J Cardiol 2000; 85:698-702.
57. de Swart H, Bar F et al. Long-term outcome and clinical results of the BiodivYsio PC-coated stent. Am J Cardiol 1998; 84(Suppl 6A):4S.
58. Cumberland D, Bonnier H, Columbo A, et al. Phosphorylcholine (PC) coated divYsio stent - initial clinical experience from an open registry. JACC 1998; 10:407C.
59. Columbo AC, Barragan P, Taylor K, et al. Phosphorylcholine (PC) coated divYsio stent in small coronary arteries: clinical experience from an open registry. Am J Cardiol 1998; 84(Suppl 6A): 61S.
60. Zheng H, Barragan P, Corcos T, et al. Clinical experience with a new biocompatible phosphorylcholine-coated coronary stent. J Invasive Cardiol 1999; 11:608-614.
61. Corcos T, Barragan P, Zheng H, et al. Clinical evaluation of a biocompatible phosphorylcholine-coated coronary stent [abstract]. Eur Heart J 1999; 20(Suppl): P1521.
62. Galli M, Bartorelli A, Bedogni F, et al. Italian BiodivYsio open registry (BiodivYsio PC-coated stent): study of clinical outcomes of the implant of a PC-coated coronary stent. J Invasive Cardiol 2000; 12:452-458.
63. Boland JL, Corbeij HAM, van der Giessen, et al. Multicentre evaluation of the phosphorylcholine-coated BiodivYsio stent in short de novo coronary lesions: The SOPHOS study. Int J Cardiol Interv 2000; 3:215-225.
64. Historical references used for MACE rate calculation were Benestent-I Study, stress trial, ASCENT trial, and AVE Microstent data. [References 20-23 in Galli M, Bartorelli A, Bedogni F, et al. Italian BiodivYsio open registry (BiodivYsio PC-coated stent): study of clinical outcomes of the implant of a PC-coated coronary stent. J Invasive Cardiol 2000; 12:452-458].
65. Akiyama T, Moussa I, Reimers B, et al. Angiographic and clinical outcome following coronary stenting of small vessels: a comparison with coronary stenting of large vessels. JACC 1998; 32: 1610-1618.
66. Serruys PW, de Jaegere P, Kiemeneij F, et al. A comparison of balloon-expandable stent implantation with balloon angioplasty in patients with coronary artery disease. N Eng J Med 1994; 331:489-495.
67. TM stent in randomised control trial (DISTINCT). Circulation 2000; 102: Suppl. 18.
68. Serruys PW, Kutryk MJB, editors. Handbook of Coronary Stents. 2 ed. London: Martin Dunitz, 1998.
69. BiodivYsio® AS OTW IFU; Benestent II Registry, Serruys PW et al. Lancet 1998; 352:673-681; ACS Multi-link Rx TRISTAR IFU; NIR on Ranger IFU; AVE Microstent II IFU; RACECAR Medtronic S670 IFU.
70. Lewis AL, Vick TA. Site-specific drug delivery from coronary stents. Drug Deliv Syst Sci (DDS&S) 2001; 1(3), 65-71.